Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium-Glucose Cotransporter 2 Inhibitors.
Saved in:
| Title: | Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium-Glucose Cotransporter 2 Inhibitors. |
|---|---|
| Authors: | Verma S; Division of Cardiac Surgery, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, ON, Canada. Subodh.Verma@unityhealth.to.; Department of Surgery, University of Toronto, Toronto, ON, Canada. Subodh.Verma@unityhealth.to.; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada. Subodh.Verma@unityhealth.to., Mudaliar S; Endocrinology/Diabetes Section, Veterans Affairs Medical Centre, San Diego, CA, USA.; Department of Medicine, University of California, San Diego, CA, USA., Greasley PJ; Early Discovery and Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. |
| Source: | Advances in therapy [Adv Ther] 2024 Jan; Vol. 41 (1), pp. 92-112. Date of Electronic Publication: 2023 Nov 09. |
| Publication Type: | Journal Article; Review; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-8652 (Electronic) Linking ISSN: 0741238X NLM ISO Abbreviation: Adv Ther |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1865-8652 |
|---|---|
| DOI: | 10.1007/s12325-023-02652-5 |
